Date: 2015-03-03
Type of information: Nomination
Compound:
Company: Fate Therapeutics (USA - CA)
Therapeutic area: Cancer - Oncology - Rare diseases - Genetic diseases - Hematological diseases
Type agreement: nomination
Action mechanism:
Disease:
Details: * On March 3, 2015, Fate Therapeutics, a biopharmaceutical company engaged in the development of programmed cellular therapeutics for the treatment of severe, life-threatening diseases, announced that Wendy Levin, M.D., M.S. will join the Company as Vice President, Clinical Development and that Walter Grubb has joined the Company as Vice President, Business Development. Additionally, the Company announced the promotion of John Ferraro to the newly-created position of Vice President, Clinical Operations.
Dr. Levin will play a critical role spearheading the Company\'s clinical development of Prohema® in patients with hematologic
malignancies and rare genetic disorders. Dr. Levin, a board-certified hematologist / oncologist with extensive experience in
clinical oncology research, joins Fate Therapeutics from MEI Pharma, where she was Vice President of Clinical Development
and Medical Affairs. Previously, she held positions of increasing responsibilities at Pfizer from 2007 to 2013, where she led a
global oncology program targeting the hedgehog pathway from first-in-human studies into later-stage development. Dr. Levin
completed her Internal Medicine Residency at the University of Southern California, and went on to complete a Hematology /
Oncology Fellowship at the University of Washington / Fred Hutchinson Cancer Research Center in Seattle.
Mr. Grubb\'s responsibilities will include the assessment, valuation and licensing of business opportunities for the Company. Mr.
Grubb was previously Executive Director of Business Development and Commercial Operations at Ambit Biosciences, where he
was responsible for multiple partnership transactions, provided commercial leadership for product candidates spanning a range
of indications and stages of development, and was instrumental in the company\'s initial public offering and ultimate acquisition
by Daiichi-Sankyo. Prior to Ambit, Mr. Grubb held positions of increasing responsibility at Neurocrine Biosciences from 2000 to
2008 that included business development, market analytics, medical affairs and product marketing.
Mr. Ferraro joined Fate Therapeutics in February 2013, and will be responsible for the Company\'s clinical operations and data
management functions. Prior to joining Fate, Mr. Ferraro was the Senior Director of Clinical Operations at GlobeImmune, Inc.,
where he established the clinical operations group and led the advancement of multiple targeted immunotherapies through the
clinical development process in the United States and in Europe. Mr. Ferraro\'s professional experience spans 20 years of
biopharmaceutical industry experience in global clinical operations and research positions at Pfizer and SmithKline Beecham.
Financial terms:
Latest news:
